Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | RECQL | P46063 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | MEN1 | O00255 | 9/20 | 0.63 |
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | MITF | O75030 | 2/20 | 0.63 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.63 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | BRAF | P15056 | 5/20 | 0.56 |
| ▸ | G6PD | P11413 | 2/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.51 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5147415 | 0.84 | KMT2A (0.68) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5147260 | 0.82 | BRAF (0.69) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5166572 | 0.81 | GSK3A (0.69) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5166576 | 0.81 | GSK3A (0.69) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5165923 | 0.81 | MAPT (1.00) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5165932 | 0.81 | MAPT (1.00) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5163906 | 0.81 | BRAF (0.81) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL3899184 | 0.81 | GSK3B (0.62) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL3899187 | 0.81 | GSK3B (0.62) | MAPTMCL1LMNARECQLKMT2A | |
| SCHEMBL5168146 | 0.81 | KMT2A (0.69) | MAPTMCL1LMNARECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718308-A4 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORP (CA) | 2007-07-18 | — | — | EP | disclosed |
| EP-1718308-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2006-11-08 | — | — | EP | disclosed |
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-12-22 | — | — | US | disclosed |
| WO-2005076695-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282840-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | MAPT 2096/4885MCL1 2677/4885LMNA 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.